Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.

Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.

To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-ty...

Full description

Bibliographic Details
Main Authors: Yu-Lin Lin, Yi-Hsin Liang, Jia-Huei Tsai, Jau-Yu Liau, Jin-Tung Liang, Been-Ren Lin, Ji-Shiang Hung, Liang-In Lin, Li-Hui Tseng, Yih-Leong Chang, Kun-Huei Yeh, Ann-Lii Cheng
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3913571?pdf=render

Similar Items

Similar Items